Lava Therapeutics Nv Expected To Post A Loss Of 59 Cents A Share: Earnings Preview

LAVA Therapeutics NV

12/08/2022 16:00

* LAVA Therapeutics NV  LVTX.OQ   LVTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 15
(estimated). 
    * The Utrecht-based  company is expected to report revenue
of
€333.33 thousand, according to the mean estimate from 3
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for LAVA Therapeutics
NV is
for a loss of 59 cents per share. For the same quarter last
year, the company reported a loss of 23 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $23​, above​ its last closing price of $2.71. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in euros). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.79       -0.81      -0.41     Beat    49.4
 Dec. 31 2022  -0.37       -0.36      -0.38     Missed  -5.6
 Sep. 30 2021  -0.28       -0.27      -0.23     Beat    13.3​
 Jun. 30 2021  -0.23       -0.23      -0.23     Met     -0.8
 ​​Mar.        -0.67       -0.67      -10.19    Missed  -1,432
 31 2021                                                .3
                                                        ​
 This summary was machine generated August 12 at 15:00 GMT.  All
figures in euros  unless otherwise stated